Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE).
Hepatitis C virus (HCV) is hyperendemic among injection drug users (IDUs). However, few scientifically proven interventions to prevent secondary transmission of HCV from infected IDUs to others exist. This report describes the design, feasibility, and baseline characteristics of participants enrolled in the Study to Reduce Intravenous Exposure (STRIVE). STRIVE was a multisite, randomized-control trial to test a behavioral intervention developed to reduce distribution of used injection equipment (needles, cookers, cottons, and rinse water) and increase health-care utilization among antibody HCV (anti-HCV) positive IDUs. STRIVE enrolled anti-HCV positive IDU in Baltimore, New York City, and Seattle; participants completed behavioral assessments and venipuncture for HIV, HCV-RNA, and liver function tests (LFTs) and were randomized to attend either a six-session, small-group, peer-mentoring intervention workshop or a time-matched, attention-control condition. Follow-up visits were conducted at 3 and 6 months. At baseline, of the 630 HCV-positive IDUs enrolled (mean age of 26 years, 60% white, 76% male), 55% reported distributive needle sharing, whereas 74, 69, and 69% reported sharing cookers, cottons, and rinse water, respectively. Health-care access was low, with 41% reporting an emergency room as their main source of medical care. Among those enrolled, 66% (418/630) were randomized: 53% (222/418) and 47% (196/418) to the intervention and control conditions, respectively. Follow-up rates were 70 and 73% for the 3- and 6-month visits, respectively. As distributive sharing of used injection equipment was common while reports of receiving HCV care were low, these findings indicate an urgent need for HCV-related interventions with IDUs and demonstrate the acceptability and feasibility to do so.
Kapadia
Farzana
F
Guttmacher Institute, New York, NY 10005, USA. fkapadia@guttmacher.org
Latka
Mary H
MH
Hagan
Holly
H
Golub
Elizabeth T
ET
Campbell
Jennifer V
JV
Coady
Micaela H
MH
Garfein
Richard S
RS
Thomas
David L
DL
Bonner
Sebastian
S
Thiel
Thelma
T
Strathdee
Steffanie A
SA
D000293:Adolescent; D000328:Adult; D001521:Behavior Therapy / Q000458:organization & administration*; D017743:Equipment Reuse; D005240:Feasibility Studies; D005260:Female; D015438:Health Behavior; D006296:Health Services / Q000706:statistics & numerical data; D006297:Health Services Accessibility / Q000458:organization & administration*; D006526:Hepatitis C / Q000209:etiology / Q000517:prevention & control* / Q000635:transmission*; D006801:Humans; D008297:Male; D016485:Needle Sharing / Q000009:adverse effects*; D011314:Preventive Health Services / Q000458:organization & administration; D012959:Socioeconomic Factors; D015819:Substance Abuse, Intravenous / Q000150:complications*